1 Report Business Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 1.2.2 Biologics 1.2.3 Biosimilars 1.3 Market by Application 1.3.1 Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 1.3.2 Immunology 1.3.3 Endocrinology 1.3.4 Others 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global Non-oncology Biopharmaceuticals Market Perspective (2017-2028) 2.2 Non-oncology Biopharmaceuticals Growth Trends by Region 2.2.1 Non-oncology Biopharmaceuticals Market Size by Region: 2017 VS 2021 VS 2028 2.2.2 Non-oncology Biopharmaceuticals Historic Market Size by Region (2017-2022) 2.2.3 Non-oncology Biopharmaceuticals Forecasted Market Size by Region (2023-2028) 2.3 Non-oncology Biopharmaceuticals Market Dynamics 2.3.1 Non-oncology Biopharmaceuticals Industry Trends 2.3.2 Non-oncology Biopharmaceuticals Market Drivers 2.3.3 Non-oncology Biopharmaceuticals Market Challenges 2.3.4 Non-oncology Biopharmaceuticals Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Non-oncology Biopharmaceuticals Players by Revenue 3.1.1 Global Top Non-oncology Biopharmaceuticals Players by Revenue (2017-2022) 3.1.2 Global Non-oncology Biopharmaceuticals Revenue Market Share by Players (2017-2022) 3.2 Global Non-oncology Biopharmaceuticals Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Players Covered: Ranking by Non-oncology Biopharmaceuticals Revenue 3.4 Global Non-oncology Biopharmaceuticals Market Concentration Ratio 3.4.1 Global Non-oncology Biopharmaceuticals Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Non-oncology Biopharmaceuticals Revenue in 2021 3.5 Non-oncology Biopharmaceuticals Key Players Head office and Area Served 3.6 Key Players Non-oncology Biopharmaceuticals Product Solution and Service 3.7 Date of Enter into Non-oncology Biopharmaceuticals Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Non-oncology Biopharmaceuticals Breakdown Data by Type 4.1 Global Non-oncology Biopharmaceuticals Historic Market Size by Type (2017-2022) 4.2 Global Non-oncology Biopharmaceuticals Forecasted Market Size by Type (2023-2028) 5 Non-oncology Biopharmaceuticals Breakdown Data by Application 5.1 Global Non-oncology Biopharmaceuticals Historic Market Size by Application (2017-2022) 5.2 Global Non-oncology Biopharmaceuticals Forecasted Market Size by Application (2023-2028) 6 North America 6.1 North America Non-oncology Biopharmaceuticals Market Size (2017-2028) 6.2 North America Non-oncology Biopharmaceuticals Market Size by Type 6.2.1 North America Non-oncology Biopharmaceuticals Market Size by Type (2017-2022) 6.2.2 North America Non-oncology Biopharmaceuticals Market Size by Type (2023-2028) 6.2.3 North America Non-oncology Biopharmaceuticals Market Share by Type (2017-2028) 6.3 North America Non-oncology Biopharmaceuticals Market Size by Application 6.3.1 North America Non-oncology Biopharmaceuticals Market Size by Application (2017-2022) 6.3.2 North America Non-oncology Biopharmaceuticals Market Size by Application (2023-2028) 6.3.3 North America Non-oncology Biopharmaceuticals Market Share by Application (2017-2028) 6.4 North America Non-oncology Biopharmaceuticals Market Size by Country 6.4.1 North America Non-oncology Biopharmaceuticals Market Size by Country (2017-2022) 6.4.2 North America Non-oncology Biopharmaceuticals Market Size by Country (2023-2028) 6.4.3 U.S. 6.4.4 Canada 7 Europe 7.1 Europe Non-oncology Biopharmaceuticals Market Size (2017-2028) 7.2 Europe Non-oncology Biopharmaceuticals Market Size by Type 7.2.1 Europe Non-oncology Biopharmaceuticals Market Size by Type (2017-2022) 7.2.2 Europe Non-oncology Biopharmaceuticals Market Size by Type (2023-2028) 7.2.3 Europe Non-oncology Biopharmaceuticals Market Share by Type (2017-2028) 7.3 Europe Non-oncology Biopharmaceuticals Market Size by Application 7.3.1 Europe Non-oncology Biopharmaceuticals Market Size by Application (2017-2022) 7.3.2 Europe Non-oncology Biopharmaceuticals Market Size by Application (2023-2028) 7.3.3 Europe Non-oncology Biopharmaceuticals Market Share by Application (2017-2028) 7.4 Europe Non-oncology Biopharmaceuticals Market Size by Country 7.4.1 Europe Non-oncology Biopharmaceuticals Market Size by Country (2017-2022) 7.4.2 Europe Non-oncology Biopharmaceuticals Market Size by Country (2023-2028) 7.4.3 Germany 7.4.4 France 7.4.5 U.K. 7.4.6 Italy 7.4.7 Russia 7.4.8 Nordic Countries 8 Asia-Pacific 8.1 Asia-Pacific Non-oncology Biopharmaceuticals Market Size (2017-2028) 8.2 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Type 8.2.1 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Type (2017-2022) 8.2.2 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Type (2023-2028) 8.2.3 Asia-Pacific Non-oncology Biopharmaceuticals Market Share by Type (2017-2028) 8.3 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Application 8.3.1 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Application (2017-2022) 8.3.2 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Application (2023-2028) 8.3.3 Asia-Pacific Non-oncology Biopharmaceuticals Market Share by Application (2017-2028) 8.4 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Region 8.4.1 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Region (2017-2022) 8.4.2 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Region (2023-2028) 8.4.3 China 8.4.4 Japan 8.4.5 South Korea 8.4.6 Southeast Asia 8.4.7 India 8.4.8 Australia 9 Latin America 9.1 Latin America Non-oncology Biopharmaceuticals Market Size (2017-2028) 9.2 Latin America Non-oncology Biopharmaceuticals Market Size by Type 9.2.1 Latin America Non-oncology Biopharmaceuticals Market Size by Type (2017-2022) 9.2.2 Latin America Non-oncology Biopharmaceuticals Market Size by Type (2023-2028) 9.2.3 Latin America Non-oncology Biopharmaceuticals Market Share by Type (2017-2028) 9.3 Latin America Non-oncology Biopharmaceuticals Market Size by Application 9.3.1 Latin America Non-oncology Biopharmaceuticals Market Size by Application (2017-2022) 9.3.2 Latin America Non-oncology Biopharmaceuticals Market Size by Application (2023-2028) 9.3.3 Latin America Non-oncology Biopharmaceuticals Market Share by Application (2017-2028) 9.4 Latin America Non-oncology Biopharmaceuticals Market Size by Country 9.4.1 Latin America Non-oncology Biopharmaceuticals Market Size by Country (2017-2022) 9.4.2 Latin America Non-oncology Biopharmaceuticals Market Size by Country (2023-2028) 9.4.3 Mexico 9.4.4 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Non-oncology Biopharmaceuticals Market Size (2017-2028) 10.2 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Type 10.2.1 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Type (2017-2022) 10.2.2 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Type (2023-2028) 10.2.3 Middle East & Africa Non-oncology Biopharmaceuticals Market Share by Type (2017-2028) 10.3 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Application 10.3.1 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Application (2017-2022) 10.3.2 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Application (2023-2028) 10.3.3 Middle East & Africa Non-oncology Biopharmaceuticals Market Share by Application (2017-2028) 10.4 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country 10.4.1 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2017-2022) 10.4.2 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2023-2028) 10.4.3 Turkey 10.4.4 Saudi Arabia 10.4.5 UAE 11 Key Players Profiles 11.1 Roche 11.1.1 Roche Company Details 11.1.2 Roche Business Overview 11.1.3 Roche Non-oncology Biopharmaceuticals Introduction 11.1.4 Roche Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) 11.1.5 Roche Recent Developments 11.2 Sanofi 11.2.1 Sanofi Company Details 11.2.2 Sanofi Business Overview 11.2.3 Sanofi Non-oncology Biopharmaceuticals Introduction 11.2.4 Sanofi Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) 11.2.5 Sanofi Recent Developments 11.3 Johnson & Johnson 11.3.1 Johnson & Johnson Company Details 11.3.2 Johnson & Johnson Business Overview 11.3.3 Johnson & Johnson Non-oncology Biopharmaceuticals Introduction 11.3.4 Johnson & Johnson Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) 11.3.5 Johnson & Johnson Recent Developments 11.4 Pfizer 11.4.1 Pfizer Company Details 11.4.2 Pfizer Business Overview 11.4.3 Pfizer Non-oncology Biopharmaceuticals Introduction 11.4.4 Pfizer Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) 11.4.5 Pfizer Recent Developments 11.5 Novo Nordisk 11.5.1 Novo Nordisk Company Details 11.5.2 Novo Nordisk Business Overview 11.5.3 Novo Nordisk Non-oncology Biopharmaceuticals Introduction 11.5.4 Novo Nordisk Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) 11.5.5 Novo Nordisk Recent Developments 11.6 Novartis 11.6.1 Novartis Company Details 11.6.2 Novartis Business Overview 11.6.3 Novartis Non-oncology Biopharmaceuticals Introduction 11.6.4 Novartis Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) 11.6.5 Novartis Recent Developments 11.7 Merck 11.7.1 Merck Company Details 11.7.2 Merck Business Overview 11.7.3 Merck Non-oncology Biopharmaceuticals Introduction 11.7.4 Merck Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) 11.7.5 Merck Recent Developments 11.8 Teva 11.8.1 Teva Company Details 11.8.2 Teva Business Overview 11.8.3 Teva Non-oncology Biopharmaceuticals Introduction 11.8.4 Teva Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) 11.8.5 Teva Recent Developments 11.9 Eli Lilly 11.9.1 Eli Lilly Company Details 11.9.2 Eli Lilly Business Overview 11.9.3 Eli Lilly Non-oncology Biopharmaceuticals Introduction 11.9.4 Eli Lilly Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) 11.9.5 Eli Lilly Recent Developments 11.10 Bristol-Myers Squibb 11.10.1 Bristol-Myers Squibb Company Details 11.10.2 Bristol-Myers Squibb Business Overview 11.10.3 Bristol-Myers Squibb Non-oncology Biopharmaceuticals Introduction 11.10.4 Bristol-Myers Squibb Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) 11.10.5 Bristol-Myers Squibb Recent Developments 11.11 GlaxoSmithKline 11.11.1 GlaxoSmithKline Company Details 11.11.2 GlaxoSmithKline Business Overview 11.11.3 GlaxoSmithKline Non-oncology Biopharmaceuticals Introduction 11.11.4 GlaxoSmithKline Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) 11.11.5 GlaxoSmithKline Recent Developments 11.12 UCB Pharma 11.12.1 UCB Pharma Company Details 11.12.2 UCB Pharma Business Overview 11.12.3 UCB Pharma Non-oncology Biopharmaceuticals Introduction 11.12.4 UCB Pharma Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) 11.12.5 UCB Pharma Recent Developments 11.13 Amgen 11.13.1 Amgen Company Details 11.13.2 Amgen Business Overview 11.13.3 Amgen Non-oncology Biopharmaceuticals Introduction 11.13.4 Amgen Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) 11.13.5 Amgen Recent Developments 11.14 AbbVie 11.14.1 AbbVie Company Details 11.14.2 AbbVie Business Overview 11.14.3 AbbVie Non-oncology Biopharmaceuticals Introduction 11.14.4 AbbVie Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) 11.14.5 AbbVie Recent Developments 11.15 Takeda 11.15.1 Takeda Company Details 11.15.2 Takeda Business Overview 11.15.3 Takeda Non-oncology Biopharmaceuticals Introduction 11.15.4 Takeda Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) 11.15.5 Takeda Recent Developments 11.16 AstraZeneca 11.16.1 AstraZeneca Company Details 11.16.2 AstraZeneca Business Overview 11.16.3 AstraZeneca Non-oncology Biopharmaceuticals Introduction 11.16.4 AstraZeneca Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) 11.16.5 AstraZeneca Recent Developments 11.17 Mylan 11.17.1 Mylan Company Details 11.17.2 Mylan Business Overview 11.17.3 Mylan Non-oncology Biopharmaceuticals Introduction 11.17.4 Mylan Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) 11.17.5 Mylan Recent Developments 11.18 LEO Pharma 11.18.1 LEO Pharma Company Details 11.18.2 LEO Pharma Business Overview 11.18.3 LEO Pharma Non-oncology Biopharmaceuticals Introduction 11.18.4 LEO Pharma Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) 11.18.5 LEO Pharma Recent Developments 11.19 Boehringer Ingelheim 11.19.1 Boehringer Ingelheim Company Details 11.19.2 Boehringer Ingelheim Business Overview 11.19.3 Boehringer Ingelheim Non-oncology Biopharmaceuticals Introduction 11.19.4 Boehringer Ingelheim Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) 11.19.5 Boehringer Ingelheim Recent Developments 11.20 Alexion Pharmaceuticals 11.20.1 Alexion Pharmaceuticals Company Details 11.20.2 Alexion Pharmaceuticals Business Overview 11.20.3 Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Introduction 11.20.4 Alexion Pharmaceuticals Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) 11.20.5 Alexion Pharmaceuticals Recent Developments 11.21 Elusys Therapeutics 11.21.1 Elusys Therapeutics Company Details 11.21.2 Elusys Therapeutics Business Overview 11.21.3 Elusys Therapeutics Non-oncology Biopharmaceuticals Introduction 11.21.4 Elusys Therapeutics Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) 11.21.5 Elusys Therapeutics Recent Developments 11.22 Swedish Orphan Biovitrum 11.22.1 Swedish Orphan Biovitrum Company Details 11.22.2 Swedish Orphan Biovitrum Business Overview 11.22.3 Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Introduction 11.22.4 Swedish Orphan Biovitrum Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) 11.22.5 Swedish Orphan Biovitrum Recent Developments 11.23 Biogen 11.23.1 Biogen Company Details 11.23.2 Biogen Business Overview 11.23.3 Biogen Non-oncology Biopharmaceuticals Introduction 11.23.4 Biogen Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) 11.23.5 Biogen Recent Developments 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Author Details 13.3 Disclaimer
List of Tables Table 1. Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028 Table 2. Key Players of Biologics Table 3. Key Players of Biosimilars Table 4. Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028 Table 5. Global Non-oncology Biopharmaceuticals Market Size by Region (US$ Million): 2017 VS 2021 VS 2028 Table 6. Global Non-oncology Biopharmaceuticals Market Size by Region (2017-2022) & (US$ Million) Table 7. Global Non-oncology Biopharmaceuticals Market Share by Region (2017-2022) Table 8. Global Non-oncology Biopharmaceuticals Forecasted Market Size by Region (2023-2028) & (US$ Million) Table 9. Global Non-oncology Biopharmaceuticals Market Share by Region (2023-2028) Table 10. Non-oncology Biopharmaceuticals Market Trends Table 11. Non-oncology Biopharmaceuticals Market Drivers Table 12. Non-oncology Biopharmaceuticals Market Challenges Table 13. Non-oncology Biopharmaceuticals Market Restraints Table 14. Global Non-oncology Biopharmaceuticals Revenue by Players (2017-2022) & (US$ Million) Table 15. Global Non-oncology Biopharmaceuticals Revenue Share by Players (2017-2022) Table 16. Global Top Non-oncology Biopharmaceuticals by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-oncology Biopharmaceuticals as of 2021) Table 17. Ranking of Global Top Non-oncology Biopharmaceuticals Companies by Revenue (US$ Million) in 2021 Table 18. Global 5 Largest Players Market Share by Non-oncology Biopharmaceuticals Revenue (CR5 and HHI) & (2017-2022) Table 19. Key Players Headquarters and Area Served Table 20. Key Players Non-oncology Biopharmaceuticals Product Solution and Service Table 21. Date of Enter into Non-oncology Biopharmaceuticals Market Table 22. Mergers & Acquisitions, Expansion Plans Table 23. Global Non-oncology Biopharmaceuticals Market Size by Type (2017-2022) & (US$ Million) Table 24. Global Non-oncology Biopharmaceuticals Revenue Market Share by Type (2017-2022) Table 25. Global Non-oncology Biopharmaceuticals Forecasted Market Size by Type (2023-2028) & (US$ Million) Table 26. Global Non-oncology Biopharmaceuticals Revenue Market Share by Type (2023-2028) Table 27. Global Non-oncology Biopharmaceuticals Market Size by Application (2017-2022) & (US$ Million) Table 28. Global Non-oncology Biopharmaceuticals Revenue Share by Application (2017-2022) Table 29. Global Non-oncology Biopharmaceuticals Forecasted Market Size by Application (2023-2028) & (US$ Million) Table 30. Global Non-oncology Biopharmaceuticals Revenue Share by Application (2023-2028) Table 31. North America Non-oncology Biopharmaceuticals Market Size by Type (2017-2022) & (US$ Million) Table 32. North America Non-oncology Biopharmaceuticals Market Size by Type (2023-2028) & (US$ Million) Table 33. North America Non-oncology Biopharmaceuticals Market Size by Application (2017-2022) & (US$ Million) Table 34. North America Non-oncology Biopharmaceuticals Market Size by Application (2023-2028) & (US$ Million) Table 35. North America Non-oncology Biopharmaceuticals Market Size by Country (2017-2022) & (US$ Million) Table 36. North America Non-oncology Biopharmaceuticals Market Size by Country (2023-2028) & (US$ Million) Table 37. Europe Non-oncology Biopharmaceuticals Market Size by Type (2017-2022) & (US$ Million) Table 38. Europe Non-oncology Biopharmaceuticals Market Size by Type (2023-2028) & (US$ Million) Table 39. Europe Non-oncology Biopharmaceuticals Market Size by Application (2017-2022) & (US$ Million) Table 40. Europe Non-oncology Biopharmaceuticals Market Size by Application (2023-2028) & (US$ Million) Table 41. Europe Non-oncology Biopharmaceuticals Market Size by Country (2017-2022) & (US$ Million) Table 42. Europe Non-oncology Biopharmaceuticals Market Size by Country (2023-2028) & (US$ Million) Table 43. Asia Pacific Non-oncology Biopharmaceuticals Market Size by Type (2017-2022) & (US$ Million) Table 44. Asia Pacific Non-oncology Biopharmaceuticals Market Size by Type (2023-2028) & (US$ Million) Table 45. Asia Pacific Non-oncology Biopharmaceuticals Market Size by Application (2017-2022) & (US$ Million) Table 46. Asia Pacific Non-oncology Biopharmaceuticals Market Size by Application (2023-2028) & (US$ Million) Table 47. Asia Pacific Non-oncology Biopharmaceuticals Market Size by Region (2017-2022) & (US$ Million) Table 48. Asia Pacific Non-oncology Biopharmaceuticals Market Size by Region (2023-2028) & (US$ Million) Table 49. Latin America Non-oncology Biopharmaceuticals Market Size by Type (2017-2022) & (US$ Million) Table 50. Latin America Non-oncology Biopharmaceuticals Market Size by Type (2023-2028) & (US$ Million) Table 51. Latin America Non-oncology Biopharmaceuticals Market Size by Application (2017-2022) & (US$ Million) Table 52. Latin America Non-oncology Biopharmaceuticals Market Size by Application (2023-2028) & (US$ Million) Table 53. Latin America Non-oncology Biopharmaceuticals Market Size by Country (2017-2022) & (US$ Million) Table 54. Latin America Non-oncology Biopharmaceuticals Market Size by Country (2023-2028) & (US$ Million) Table 55. Middle East and Africa Non-oncology Biopharmaceuticals Market Size by Type (2017-2022) & (US$ Million) Table 56. Middle East and Africa Non-oncology Biopharmaceuticals Market Size by Type (2023-2028) & (US$ Million) Table 57. Middle East and Africa Non-oncology Biopharmaceuticals Market Size by Application (2017-2022) & (US$ Million) Table 58. Middle East and Africa Non-oncology Biopharmaceuticals Market Size by Application (2023-2028) & (US$ Million) Table 59. Middle East and Africa Non-oncology Biopharmaceuticals Market Size by Country (2017-2022) & (US$ Million) Table 60. Middle East and Africa Non-oncology Biopharmaceuticals Market Size by Country (2023-2028) & (US$ Million) Table 61. Roche Company Details Table 62. Roche Business Overview Table 63. Roche Non-oncology Biopharmaceuticals Product Table 64. Roche Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million) Table 65. Roche Recent Developments Table 66. Sanofi Company Details Table 67. Sanofi Business Overview Table 68. Sanofi Non-oncology Biopharmaceuticals Product Table 69. Sanofi Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million) Table 70. Sanofi Recent Developments Table 71. Johnson & Johnson Company Details Table 72. Johnson & Johnson Business Overview Table 73. Johnson & Johnson Non-oncology Biopharmaceuticals Product Table 74. Johnson & Johnson Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million) Table 75. Johnson & Johnson Recent Developments Table 76. Pfizer Company Details Table 77. Pfizer Business Overview Table 78. Pfizer Non-oncology Biopharmaceuticals Product Table 79. Pfizer Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million) Table 80. Pfizer Recent Developments Table 81. Novo Nordisk Company Details Table 82. Novo Nordisk Business Overview Table 83. Novo Nordisk Non-oncology Biopharmaceuticals Product Table 84. Novo Nordisk Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million) Table 85. Novo Nordisk Recent Developments Table 86. Novartis Company Details Table 87. Novartis Business Overview Table 88. Novartis Non-oncology Biopharmaceuticals Product Table 89. Novartis Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million) Table 90. Novartis Recent Developments Table 91. Merck Company Details Table 92. Merck Business Overview Table 93. Merck Non-oncology Biopharmaceuticals Product Table 94. Merck Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million) Table 95. Merck Recent Developments Table 96. Teva Company Details Table 97. Teva Business Overview Table 98. Teva Non-oncology Biopharmaceuticals Product Table 99. Teva Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million) Table 100. Teva Recent Developments Table 101. Eli Lilly Company Details Table 102. Eli Lilly Business Overview Table 103. Eli Lilly Non-oncology Biopharmaceuticals Product Table 104. Eli Lilly Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million) Table 105. Eli Lilly Recent Developments Table 106. Bristol-Myers Squibb Company Details Table 107. Bristol-Myers Squibb Business Overview Table 108. Bristol-Myers Squibb Non-oncology Biopharmaceuticals Product Table 109. Bristol-Myers Squibb Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million) Table 110. Bristol-Myers Squibb Recent Developments Table 111. GlaxoSmithKline Company Details Table 112. GlaxoSmithKline Business Overview Table 113. GlaxoSmithKline Non-oncology Biopharmaceuticals Product Table 114. GlaxoSmithKline Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million) Table 115. GlaxoSmithKline Recent Developments Table 116. UCB Pharma Company Details Table 117. UCB Pharma Business Overview Table 118. UCB Pharma Non-oncology Biopharmaceuticals Product Table 119. UCB Pharma Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million) Table 120. UCB Pharma Recent Developments Table 121. Amgen Company Details Table 122. Amgen Business Overview Table 123. Amgen Non-oncology Biopharmaceuticals Product Table 124. Amgen Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million) Table 125. Amgen Recent Developments Table 126. AbbVie Company Details Table 127. AbbVie Business Overview Table 128. AbbVie Non-oncology Biopharmaceuticals Product Table 129. AbbVie Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million) Table 130. AbbVie Recent Developments Table 131. Takeda Company Details Table 132. Takeda Business Overview Table 133. Takeda Non-oncology Biopharmaceuticals Product Table 134. Takeda Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million) Table 135. Takeda Recent Developments Table 136. AstraZeneca Company Details Table 137. AstraZeneca Business Overview Table 138. AstraZeneca Non-oncology Biopharmaceuticals Product Table 139. AstraZeneca Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million) Table 140. AstraZeneca Recent Developments Table 141. Mylan Company Details Table 142. Mylan Business Overview Table 143. Mylan Non-oncology Biopharmaceuticals Product Table 144. Mylan Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million) Table 145. Mylan Recent Developments Table 146. LEO Pharma Company Details Table 147. LEO Pharma Business Overview Table 148. LEO Pharma Non-oncology Biopharmaceuticals Product Table 149. LEO Pharma Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million) Table 150. LEO Pharma Recent Developments Table 151. Boehringer Ingelheim Company Details Table 152. Boehringer Ingelheim Business Overview Table 153. Boehringer Ingelheim Non-oncology Biopharmaceuticals Product Table 154. Boehringer Ingelheim Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million) Table 155. Boehringer Ingelheim Recent Developments Table 156. Alexion Pharmaceuticals Company Details Table 157. Alexion Pharmaceuticals Business Overview Table 158. Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Product Table 159. Alexion Pharmaceuticals Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million) Table 160. Alexion Pharmaceuticals Recent Developments Table 161. Elusys Therapeutics Company Details Table 162. Elusys Therapeutics Business Overview Table 163. Elusys Therapeutics Non-oncology Biopharmaceuticals Product Table 164. Elusys Therapeutics Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million) Table 165. Elusys Therapeutics Recent Developments Table 166. Swedish Orphan Biovitrum Company Details Table 167. Swedish Orphan Biovitrum Business Overview Table 168. Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Product Table 169. Swedish Orphan Biovitrum Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million) Table 170. Swedish Orphan Biovitrum Recent Developments Table 171. Biogen Company Details Table 172. Biogen Business Overview Table 173. Biogen Non-oncology Biopharmaceuticals Product Table 174. Biogen Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million) Table 175. Biogen Recent Developments Table 176. Research Programs/Design for This Report Table 177. Key Data Information from Secondary Sources Table 178. Key Data Information from Primary Sources List of Figures Figure 1. Global Non-oncology Biopharmaceuticals Market Share by Type: 2021 VS 2028 Figure 2. Biologics Features Figure 3. Biosimilars Features Figure 4. Global Non-oncology Biopharmaceuticals Market Share by Application: 2021 VS 2028 Figure 5. Immunology Case Studies Figure 6. Endocrinology Case Studies Figure 7. Others Case Studies Figure 8. Non-oncology Biopharmaceuticals Report Years Considered Figure 9. Global Non-oncology Biopharmaceuticals Market Size (US$ Million), Year-over-Year: 2017-2028 Figure 10. Global Non-oncology Biopharmaceuticals Market Size, (US$ Million), 2017 VS 2021 VS 2028 Figure 11. Global Non-oncology Biopharmaceuticals Market Share by Region: 2021 VS 2028 Figure 12. Global Non-oncology Biopharmaceuticals Market Share by Players in 2021 Figure 13. Global Top Non-oncology Biopharmaceuticals Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-oncology Biopharmaceuticals as of 2021) Figure 14. The Top 10 and 5 Players Market Share by Non-oncology Biopharmaceuticals Revenue in 2021 Figure 15. North America Non-oncology Biopharmaceuticals Market Size YoY (2017-2028) & (US$ Million) Figure 16. North America Non-oncology Biopharmaceuticals Market Size Market Share by Type (2017-2028) Figure 17. North America Non-oncology Biopharmaceuticals Market Size Market Share by Application (2017-2028) Figure 18. North America Non-oncology Biopharmaceuticals Market Size Share by Country (2017-2028) Figure 19. United States Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million) Figure 20. Canada Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million) Figure 21. Europe Non-oncology Biopharmaceuticals Market Size YoY (2017-2028) & (US$ Million) Figure 22. Europe Non-oncology Biopharmaceuticals Market Size Market Share by Type (2017-2028) Figure 23. Europe Non-oncology Biopharmaceuticals Market Size Market Share by Application (2017-2028) Figure 24. Europe Non-oncology Biopharmaceuticals Market Size Share by Country (2017-2028) Figure 25. Germany Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million) Figure 26. France Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million) Figure 27. U.K. Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million) Figure 28. Italy Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million) Figure 29. Russia Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million) Figure 30. Nordic Countries Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million) Figure 31. Asia-Pacific Non-oncology Biopharmaceuticals Market Size YoY (2017-2028) & (US$ Million) Figure 32. Asia Pacific Non-oncology Biopharmaceuticals Market Size Market Share by Type (2017-2028) Figure 33. Asia Pacific Non-oncology Biopharmaceuticals Market Size Market Share by Application (2017-2028) Figure 34. Asia Pacific Non-oncology Biopharmaceuticals Market Size Share by Region (2017-2028) Figure 35. China Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million) Figure 36. Japan Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million) Figure 37. South Korea Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million) Figure 38. Southeast Asia Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million) Figure 39. India Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million) Figure 40. Australia Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million) List of Figures Figure 41. Latin America Non-oncology Biopharmaceuticals Market Size YoY (2017-2028) & (US$ Million) Figure 42. Latin America Non-oncology Biopharmaceuticals Market Size Market Share by Type (2017-2028) Figure 43. Latin America Non-oncology Biopharmaceuticals Market Size Market Share by Application (2017-2028) Figure 44. Latin America Non-oncology Biopharmaceuticals Market Size Share by Country (2017-2028) Figure 45. Mexico Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million) Figure 46. Brazil Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million) Figure 47. Middle East & Africa Non-oncology Biopharmaceuticals Market Size YoY (2017-2028) & (US$ Million) Figure 48. Middle East and Africa Non-oncology Biopharmaceuticals Market Size Market Share by Type (2017-2028) Figure 49. Middle East and Africa Non-oncology Biopharmaceuticals Market Size Market Share by Application (2017-2028) Figure 50. Middle East and Africa Non-oncology Biopharmaceuticals Market Size Share by Country (2017-2028) Figure 51. Turkey Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million) Figure 52. Saudi Arabia Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million) Figure 53. UAE Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million) Figure 54. Roche Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022) Figure 55. Sanofi Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022) Figure 56. Johnson & Johnson Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022) Figure 57. Pfizer Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022) Figure 58. Novo Nordisk Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022) Figure 59. Novartis Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022) Figure 60. Merck Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022) Figure 61. Teva Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022) Figure 62. Eli Lilly Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022) Figure 63. Bristol-Myers Squibb Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022) Figure 64. GlaxoSmithKline Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022) Figure 65. UCB Pharma Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022) Figure 66. Amgen Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022) Figure 67. AbbVie Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022) Figure 68. Takeda Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022) Figure 69. AstraZeneca Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022) Figure 70. Mylan Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022) Figure 71. LEO Pharma Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022) Figure 72. Boehringer Ingelheim Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022) Figure 73. Alexion Pharmaceuticals Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022) Figure 74. Elusys Therapeutics Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022) Figure 75. Swedish Orphan Biovitrum Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022) Figure 76. Biogen Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022) Figure 77. Bottom-up and Top-down Approaches for This Report Figure 78. Data Triangulation Figure 79. Key Executives Interviewed